InterVenn

InterVenn Biosciences was founded in 2017 by a team of visionary scientists and entrepreneurs: Nobel Laureate Dr. Carolyn Bertozzi, distinguished professor Dr. Carlito Lebrilla, and AI/ML expert Aldo Carrascoso. Their mission was to revolutionize healthcare through the innovative use of AI-driven glycoproteomics, a field that studies the structure and function of proteins with sugar molecules attached, which are crucial in many biological processes.

InterVenn's journey has been marked by significant milestones. In August 2021, the company secured a substantial $201 million in a Series C funding round. This investment was pivotal in advancing their glycoproteomic platform and liquid-biopsy assays, which are designed to improve early cancer detection and drug development. The funding round was led by prominent investors, including SoftBank Group, underscoring the confidence in InterVenn's potential to transform the healthcare landscape.

Throughout its development, InterVenn has focused on leveraging artificial intelligence to enhance the accuracy and efficiency of its diagnostic tools. By integrating AI with glycoproteomics, the company aims to provide more precise and personalized healthcare solutions, addressing unmet needs in oncology and beyond.

As of now, InterVenn continues to innovate and expand its capabilities, with an eye towards future growth and potential public offering. The company's commitment to harnessing cutting-edge technology for medical advancement positions it as a leader in the biotech industry, promising to make significant impacts on patient outcomes worldwide.